Cytokinetics (CYTK) Common Equity (2016 - 2024)
Historic Common Equity for Cytokinetics (CYTK) over the last 16 years, with Q3 2024 value amounting to -$13.9 million.
- Cytokinetics' Common Equity rose 9682.98% to -$13.9 million in Q3 2024 from the same period last year, while for Sep 2024 it was -$13.9 million, marking a year-over-year increase of 9682.98%. This contributed to the annual value of -$386.3 million for FY2023, which is 25803.8% down from last year.
- Latest data reveals that Cytokinetics reported Common Equity of -$13.9 million as of Q3 2024, which was up 9682.98% from $108.6 million recorded in Q2 2024.
- In the past 5 years, Cytokinetics' Common Equity ranged from a high of $249.0 million in Q3 2021 and a low of -$438.8 million during Q3 2023
- Its 5-year average for Common Equity is -$45.7 million, with a median of -$13.9 million in 2024.
- In the last 5 years, Cytokinetics' Common Equity surged by 113669.2% in 2020 and then crashed by 264645.43% in 2023.
- Over the past 5 years, Cytokinetics' Common Equity (Quarter) stood at $113.4 million in 2020, then skyrocketed by 115.08% to $243.9 million in 2021, then plummeted by 144.25% to -$107.9 million in 2022, then crashed by 258.04% to -$386.3 million in 2023, then skyrocketed by 96.4% to -$13.9 million in 2024.
- Its Common Equity was -$13.9 million in Q3 2024, compared to $108.6 million in Q2 2024 and -$396.2 million in Q1 2024.